Insider Transactions in Q2 2024 at Inhibrx, Inc. (INBX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 30
2024
|
Viking Global Investors LP |
SELL
Other acquisition or disposition
|
Indirect |
7,150,826
-100.0%
|
$214,524,780
$30.0 P/Share
|
|
May 30
2024
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,055,553
-100.0%
|
$61,666,590
$30.0 P/Share
|
|
May 30
2024
|
Douglas Forsyth Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
598,257
-100.0%
|
$17,947,710
$30.0 P/Share
|
|
May 30
2024
|
Jon Faiz Kayyem Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,274,301
-100.0%
|
$98,229,030
$30.0 P/Share
|
|
May 30
2024
|
Mark Lappe Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,045,654
-100.0%
|
$91,369,620
$30.0 P/Share
|
|
May 28
2024
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
300,000
-14.74%
|
$10,200,000
$34.3 P/Share
|